In this episode, Pip and Rich discuss the FRAIL-AF study: Joosten et al. Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. 2024;149:279–289. This trial randomised the switching of elderly frail patients who were established on a vitamin K antagonist to either remain on this treatment or switch to a direct oral anticoagulant. They found increased rates of bleeding in the switch arm. However, there is a lot of detail that is not in the abstract! Pip and Rich take a deep dive into the manuscript, discuss their thoughts with Chief Investigator, Geert Jan Geersing on the trial, and put the findings into context with consultant haematologist David Sutton. To read more about this trial check out Rich's blog on it: https://classicalcompass.substack.com/p/frail-af Links FRAIL-AF: https://www.ahajournals.org/doi/epdf/10.1161/CIRCULATIONAHA.123.066485

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related